13F Holdings
中文EN

ZTS Zoetis Inc.

Pharmaceutical Preparations · NYSE · SEC CIK 1555280 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY1.0%
TTM net income YoY-5.5%
TTM EPS YoY0.7%
Revenue 3-yr CAGR4.3%
Net income 3-yr CAGR2.9%

Margins

Gross margin71.4%
Operating margin—
Net margin26.1%
FCF margin24.0%
EBITDA margin—

Returns

ROE57.1%
ROA16.4%
ROIC (approx.)—
Asset turnover0.63x

Leverage & solvency

Liabilities / assets78.1%
Debt / equity2.74x
Current ratio2.35x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.12x
Accruals ratio-1.9%
Payout ratio—
Capex / revenue5.2%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$9.47B$9.26B$8.54B$8.08B$7.78B
Cost of revenue$2.67B$2.72B$2.56B$2.45B$2.30B
Gross profit$6.80B$6.54B$5.98B$5.63B$5.47B
R&D expense$698.00M$686.00M$614.00M$539.00M$508.00M
SG&A expense$2.38B$2.32B$2.15B$2.01B$2.00B
Interest expense$222.00M$225.00M$239.00M$221.00M$224.00M
Pretax income$3.36B$3.13B$2.94B$2.66B$2.49B
Income tax$687.00M$637.00M$596.00M$545.00M$454.00M
Net income$2.67B$2.49B$2.34B$2.11B$2.04B
EPS (basic)6.035.475.084.514.29
EPS (diluted)6.025.475.074.494.27
Dividends declared per share2.031.801.561.351.07
Weighted avg. shares (diluted)443.83M454.85M462.27M470.38M476.72M
Balance sheet
Cash & equivalents$2.45B$2.11B$2.04B$3.58B$3.48B
Short-term investments$0————
Receivables$1.41B$1.32B$1.30B$1.22B$1.13B
Inventory$2.46B$2.31B$2.56B$2.35B$1.92B
Current assets$6.77B$5.99B$6.34B$7.51B$6.93B
PP&E, net$3.69B$3.39B$3.20B$2.75B$2.42B
Goodwill$2.77B$2.72B$2.76B$2.75B$2.68B
Intangibles$998.00M$1.13B$1.34B$1.38B$1.47B
Total assets$15.49B$14.24B$14.29B$14.93B$13.90B
Current liabilities$2.17B$3.41B$1.89B$3.17B$1.80B
Short-term debt$0$1.35B$0$1.35B$0
Long-term debt$9.04B$5.22B$6.56B$6.55B$6.59B
Total debt$9.04B$6.57B$6.56B$7.90B$6.59B
Total liabilities$12.07B$9.47B$9.29B$10.52B$9.36B
Shareholders' equity$3.42B$4.77B$5.00B$4.41B$4.54B
Net debt$6.59B$4.46B$4.52B$4.32B$3.11B
Shares outstanding424.93M448.47M458.37M463.81M472.57M
Cash flow statement
Operating cash flow$2.90B$2.95B$2.35B$1.91B$2.21B
Capital expenditure$621.00M$655.00M$732.00M$586.00M$477.00M
Free cash flow$2.28B$2.30B$1.62B$1.33B$1.74B
Investing cash flow-$748.00M-$315.00M-$777.00M-$883.00M-$458.00M
Financing cash flow-$1.87B-$2.66B-$3.11B-$904.00M-$1.86B
Depreciation & amortization$487.00M$497.00M$491.00M$465.00M$448.00M
Stock-based compensation$83.00M$74.00M$60.00M$62.00M$58.00M
Share buybacks$3.23B$1.86B$1.09B$1.59B$743.00M

Free plan shows the latest 5 periods; Pro shows all 15 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.